BMY
Bristol-Myers Squibb Company · Healthcare · Drug Manufacturers - General
Last
$60.39
+$1.43 (+2.42%) 3:06 PM ET
Prev close $58.96
Open $58.90
Day high $60.47
Day low $58.55
Volume 6,420,743
Avg vol 12,278,936
Mkt cap
$118.20B
P/E ratio
17.50
FY Revenue
$48.19B
EPS
3.45
Gross Margin
71.08%
Sector
Healthcare
AI report sections
BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb is trading near the top of its 52-week range with firm upward price momentum over the past 3–6 months and multiple bullish technical signals, while momentum indicators approach overbought territory. Fundamentally, the company combines high margins, rising earnings, and strong free cash flow generation with elevated leverage and a recent decline in operating cash flow growth. Valuation appears moderate relative to cash generation, supported by a near-4% dividend yield and double-digit free cash flow yield, while short interest remains low despite a high short-volume share of daily trading.
AI summarized at 4:07 PM ET, 2026-03-02
AI summary scores
INTRADAY: 68 SWING: 77 LONG: 74
Volume vs average
Intraday (cumulative)
+35% (Above avg)
Vol/Avg: 1.35×
RSI
49.73 (Neutral)
Neutral (40–60)
MACD momentum
Intraday
-0.01 (Weak)
MACD: 0.01 Signal: 0.02
Short-Term
-0.09 (Weak)
MACD: -0.25 Signal: -0.16
Long-Term
-0.18 (Weak)
MACD: 0.19 Signal: 0.37
Intraday trend score 84.09

Latest news

BMY 12 articles Positive: 8 Neutral: 3 Negative: 1
Neutral GlobeNewswire Inc. • Researchandmarkets.Com
Alpha Thalassemia (US, EU4, UK, and Japan) Market Insights, Epidemiology, and Forecasts 2022-2025 & 2025-2036

The alpha thalassemia market is expected to expand significantly through 2036, driven by rising prevalence and advancements in diagnostics and gene therapies. Key players Agios Pharmaceuticals and Novo Nordisk are leading development efforts with emerging drugs like PYRUKYND and etavopivat progressing through clinical trials, though no gene therapies are currently approved for the condition.

AGIO NVO BMY CELGR alpha thalassemia gene therapy clinical trials market forecast
Sentiment note

Listed as a featured company but no specific developments, clinical progress, or market activities related to alpha thalassemia are mentioned in the article.

Neutral The Motley Fool • Jack Delaney
Which Dividend Pharma Stock Should a Value Investor Choose Today?

Bristol Myers Squibb appears to be a value investment opportunity with a forward P/E ratio of 9.5, a 4.2% dividend yield, and 17 consecutive years of dividend increases. However, investors should be aware of concerns including declining legacy portfolio revenue (from $25.7B to $21.8B), an upcoming patent cliff for its blood thinner drug Eliquis, and $47B in debt. The company's growth portfolio is expanding and the Orbital Therapeutics acquisition could help offset legacy revenue losses through RNA medicine development.

BMY CELGR JNJ MRK dividend stocks pharmaceutical sector value investing patent cliff
Sentiment note

While BMY presents attractive valuation metrics (low P/E ratio, high dividend yield, stable revenue), significant headwinds exist including declining legacy revenue, upcoming patent cliffs on key drugs like Eliquis, and high debt levels. The company's growth portfolio expansion and Orbital Therapeutics acquisition offer potential upside, but execution risk remains. The neutral sentiment reflects both the value opportunity and legitimate market concerns.

Positive The Motley Fool • Prosper Junior Bakiny
2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap

The article recommends CVS Health and Bristol Myers Squibb as recession-resistant dividend stocks worth buying at current valuations. Both companies have maintained their dividends through economic downturns over the past 20 years and operate in healthcare sectors that perform well during recessions. CVS trades at 10.3x forward earnings with a 3.37% dividend yield, while Bristol Myers trades at 9.5x forward earnings with a 4.20% dividend yield.

CVS BMY CELGR recession-resistant stocks dividend stocks healthcare sector economic downturn dividend yield
Sentiment note

Recommended as a top pick for income seekers due to particularly cheap valuation at 9.5x forward earnings, strong dividend history without cuts or suspensions over 20 years, diversified medicine portfolio across therapeutic areas that perform well in recessions, and new product launches including subcutaneous Opdivo formulation to offset patent cliff challenges.

Positive GlobeNewswire Inc. • Researchandmarkets.Com
7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments

The SLE and LN market is projected to grow from $2.4 billion in 2024 to $5.9 billion by 2034 (9.6% CAGR), driven by 10 late-stage pipeline drugs offering improved safety and efficacy over current generic treatments. However, growth faces headwinds from biosimilar competition and high treatment costs limiting adoption rates.

ABBV GSK AZN RHHBY Systemic Lupus Erythematosus Lupus Nephritis biologic therapies steroid-sparing treatments
Sentiment note

Identified as a current and future competitor in the growing SLE/LN market with pipeline potential

Positive GlobeNewswire Inc. • Oxford Biotherapeutics
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours

Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb to discover and develop novel T-cell engager therapies for solid tumours using OBT's OGAP®-Verify platform. This marks OBT's third major pharma partnership in 12 months, with the company receiving upfront payments and potential milestone payments and royalties.

BMY CELGR T-cell engagers solid tumours OGAP-Verify platform immuno-oncology antibody drug conjugates strategic collaboration
Sentiment note

BMS is expanding its oncology pipeline through a strategic partnership with a validated discovery platform company. The collaboration provides access to differentiated T-cell engager candidates for solid tumours, an area of significant therapeutic interest, without bearing early-stage discovery costs.

Positive GlobeNewswire Inc. • Delveinsight
Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

The interstitial lung disease market is projected to grow at a CAGR of 8.7% from 2026-2036, driven by emerging therapies and pipeline candidates. The market was valued at USD 6 billion in 2025 across seven major markets, with the US accounting for 83% of the market. Key developments include FDA approval of nerandomilast (JASCAYD) for progressive pulmonary fibrosis and multiple late-stage candidates addressing immune dysregulation and fibrotic signaling.

GSK INSM GOSS LQDA interstitial lung disease ILD market growth emerging therapies antifibrotic drugs
Sentiment note

Bristol-Myers Squibb's Admilparant (BMS-986278) is highlighted as a mid- to late-stage candidate addressing fibrotic signaling in the expanding ILD pipeline.

Positive Investing.com • Jaachi Mbachu, Aci
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime

President Trump signed an executive order imposing 100% tariffs on imported pharmaceuticals, with 13 drug companies already exempt through Most Favored Nation (MFN) pricing agreements. Companies that signed deals and committed to U.S. manufacturing face 0% tariffs through 2029, while non-signatories face the full 100% levy starting July 31. The tariff threat has triggered over $150 billion in domestic manufacturing investments from deal-signing companies.

LLY JNJ PFE AMGN pharmaceutical tariffs MFN pricing agreements drug manufacturing onshoring investments
Sentiment note

Signed MFN deal securing 0% tariff through 2029, benefits from tariff wall protection against non-deal competitors

Positive GlobeNewswire Inc. • Researchandmarkets.Com
Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030: Key Trends, Investment Opportunities and Competitive Strategies Analyzed

The global bile duct cancer market is projected to expand from $2.59 billion in 2025 to $3.89 billion by 2030, growing at an 8.4% CAGR. Growth is driven by advancements in early diagnostics, increased adoption of immunotherapy and targeted therapies, AI-assisted diagnostics, and rising prevalence of liver diseases. Major pharmaceutical companies are introducing innovative treatments and forming strategic partnerships to enhance patient outcomes.

ABBV BMY CELGR AZN bile duct cancer oncology market immunotherapy targeted therapy
Sentiment note

Identified as a major player in the expanding bile duct cancer market with opportunities to capitalize on growing demand for oncology treatments.

Positive GlobeNewswire Inc. • Researchandmarkets.Com
Esophageal Cancer Market to Grow from $1.65 Billion in 2026 to $2.37 Billion by 2030: Pfizer, Roche, Merck & Co. Dominate

The global esophageal cancer market is projected to grow at a CAGR of 9.5% from $1.65 billion in 2026 to $2.37 billion by 2030, driven by advancements in precision oncology, immunotherapies, and minimally invasive procedures. Major pharmaceutical companies including Pfizer, Roche, and Merck are leading the market through product innovation and personalized cancer care solutions.

PFE RHHBY MRK NVS esophageal cancer oncology market precision medicine immunotherapy
Sentiment note

Featured as a key player in the esophageal cancer market with participation in advancing treatment options.

Positive The Motley Fool • Eric Volkman
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.

AbbVie and Bristol Myers Squibb are highlighted as exceptions in the healthcare sector, offering above-average dividend yields and consistent dividend growth. AbbVie, a Dividend King with a 3.4% yield, has successfully transitioned from its blockbuster drug Humira to new treatments Skyrizi and Rinvoq. Bristol Myers Squibb, yielding 4.4%, is navigating patent cliffs through innovation in its oncology portfolio, making both attractive for patient, buy-and-hold dividend investors.

ABBV BMY CELGR ABT dividend stocks healthcare sector dividend yield Dividend King
Sentiment note

Offers attractive 4.4% dividend yield with strong free cash flow ($12.8B last year) more than double dividend requirements. Growth portfolio showing 16% year-over-year revenue growth mitigates legacy portfolio decline. Positioned well for long-term buy-and-hold investors despite near-term patent cliff challenges.

Negative The Motley Fool • David Jagielski, Cpa
Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?

Bristol Myers Squibb offers an attractive 4.4% dividend yield and has raised dividends for 17 consecutive years, but the author recommends against buying due to significant patent cliffs on key drugs like Eliquis and Opdivo. With revenue expected to decline from $48.2 billion to $46-47.5 billion, there is substantial uncertainty about the company's ability to maintain its dividend payments in the coming years.

BMY CELGR dividend stock patent cliff healthcare dividend yield pharmaceutical revenue decline
Sentiment note

The article expresses concern about Bristol Myers' future despite its strong dividend history. Key concerns include upcoming patent cliffs on major drugs (Eliquis, Opdivo), flat/declining revenue projections, and uncertainty about dividend sustainability. The author explicitly recommends against buying the stock, citing too much business uncertainty to justify it as a reliable dividend investment.

Neutral Benzinga • Vandana Singh
Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma

The FDA approved Bristol Myers Squibb's Opdivo (nivolumab) combined with chemotherapy (AVD) for previously untreated Stage III or IV classical Hodgkin lymphoma in patients 12 years and older. The approval was based on Study CA209-8UT showing superior progression-free survival with a hazard ratio of 0.42. Despite the regulatory win, BMY stock declined 1.33% to $57.34 on the announcement day.

BMY CELGR FDA approval Opdivo nivolumab Hodgkin lymphoma chemotherapy AVD
Sentiment note

While the FDA approval represents a positive regulatory achievement for Opdivo's expanded indication in untreated Hodgkin lymphoma with strong clinical efficacy data (hazard ratio 0.42), the stock declined 1.33% on the announcement, suggesting the market may have already priced in this approval or investors had higher expectations. The approval is incremental rather than transformative, as Opdivo already generated $5.9 billion in 2025 revenues.

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal